Autosomal dominant polycystic kidney disease (ADPKD) arises primarily due to Pkd1 mutations and is characterised by increased kidney epithelial proliferation. The Janus Kinase and Signal Transducers and Activators of Transcription (JAK-STAT) is a proliferation regulating pathway implicated in ADPKD. Curcumin, an anti-inflammatory phytochemical, has been shown to limit murine cystogenesis possibly via JAK-STAT. However, the mechanisms employed by curcumin to inhibit JAK-STAT are uncertain. We treated ADPKD-derived renal epithelial cells with curcumin at different concentrations over 9 days and studied their growth in organotypic cystforming assays. Curcumin potently blocked cystic growth in human and mouse renal epithelial cells without requiring any additional cell types, suggesting a direct effect on kidney epithelial cells. The level of tyrosine phosphorylated-STAT3 was reduced within 1 hour of curcumin treatment in a dose-dependent manner. While total STAT3 protein levels remained unaltered, suggesting that curcumin reduces phosphorylation of STAT3 possibly via JAK2, a tyrosine kinase upstream of STAT3. Mechanistically, curcumin caused JAK2 to move into an insoluble fraction, without causing JAK2 proteosomal-degradation. Instead curcumin led to JAK2 to accumulate into aggresomes, which are known depots for inactivated enzymes. We studied JAK2 expression in kidneys of the Pkd1 nl/nl mice, which spontaneously develop progressive ADPKD. JAK2 was highly expressed in cyst-lining renal epithelial cells at 5 and 10 weeks of age, suggesting a potential role in ADPKD pathophysiology. Collectively, these data suggest that curcumin reduces STAT3 signalling and cystic growth by inactivating JAK2, thus selective JAK2 inhibition may be of therapeutic benefit in ADPKD.
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is a devastating multi-organ disease, affecting over 9 million people worldwide. It is a genetic disorder that predominately arises due to mutations in the Pkd1 gene. Pkd1 encodes for polycystin-1, a large protein with unknown function. Patients with ADPKD develop bilateral kidney cysts which become progressively enlarged, pushing the renal parenchyma, eventually causing end-stage renal failure. The majority of patients will lose kidney function by the age of 55 and will require renal replacement therapy. Mutations in polycystins also cause a strong vascular phenotype associated with hypertension and aneurysms (1, 2) . Currently there is no cure for ADPKD and only a single approved therapy, Tolvaptan (a V2 vasopressin receptor antagonist), which carries significant side effects precluding its use in the majority of patients (3). Therefore, a major biomedical challenge is to identify novel therapeutic targets to slow down the progression of cystic growth.
We have previously shown that the evolutionarily conserved JAK2-STAT5 pathway is abnormally activated in, and contributes to, ADPKD (4). Others have also shown that certain components of the JAK-STAT pathway are misregulated in ADPKD, and likely to drive disease (5) (6) (7) (8) . We therefore predict that inhibition of JAK-STAT may be of therapeutic benefit in ADPKD. JAK-STAT activity can be modified by a number of drugs including curcumin.
Curcumin (diferuloylmethane) is a natural phenol and major component of turmeric, derived from the rhizomes of the plant Curcuma longa (9). It exhibits strong antioxidant, anti-tumour and anti-inflammatory pharmacological properties (10). Curcumin has been shown to limit the growth of cysts in murine models of ADPKD (11), and it is currently being trialled as a therapy for the vascular phenotype in young patients and children with ADPKD (clinicaltrials.gov).
The precise mechanism(s) utilised by curcumin to confer kidney protection in ADPKD are unknown. In non-renal systems, curcumin was found to be a STAT3 inhibitor, however the mechanisms underlying STAT3 inhibition are unknown (12) (13) (14) . In agreement with this, treatment of Pkd nl/nl mice with curcumin resulted in reduced STAT3 activation which correlated with lowered cystic burden (11). However, whether curcumin protects the kidney primarily via STAT3 inhibition is unknown. It is also unknown whether systemic administration of curcumin leads to kidney protection via affecting either kidney epithelial cells directly or alternatively via a mechanism not involving the kidneys.
In this paper, we show that curcumin inhibits in vitro cyst growth by acting directly on renal epithelial cells without requiring any other cell types (cell autonomous actions). Moreover, mechanistically, we show that curcumin blocks STAT3 activity by modulating JAK2. Finally, we provide first evidence that JAK2 is highly expressed in cyst-lining cells of the kidney in a murine model of ADPKD and suggest it may play an important role in ADPKD.
RESULTS

Curcumin inhibits cystic growth in vitro.
Inhibition of cystic growth, previously illustrated in murine ADPKD models (11), shows that curcumin is capable of protecting the kidneys in vivo. However, whether it acts directly on kidney cells or indirectly via involving other cell types is currently unknown. To address this, three-dimensional organotypic cyst assays of renal tubular epithelial cells, derived from ADPKD patients, were employed ( Fig  1) . Three cell lines were investigated, OX161 (Fig 1A) , SKI-001 ( Fig 1B) and mouse derived ADPKD cells F1 Pkd1 -/-( Fig 1C) . Pictures of the cysts were taken at day 0, day 2, 6 and 9. We found that 100μM and 50μM of curcumin were sufficient to cause a statistically significant reduction in the size of cysts over time in all cell lines tested, when compared to DMSOtreated cells. Curcumin caused both a dose-and time-dependent reduction in cyst diameter with a pattern consistent in all three independent ADPKD lines investigated. These data show that curcumin is a potent inhibitor of cystic growth via targeting renal tubular epithelial growth in a cell-autonomous manner.
Curcumin potently inhibits STAT3 tyrosine phosphorylation.
Studies in non-renal systems have suggested that curcumin might be a JAK-STAT inhibitor (15-17), however whether curcumin inhibits the JAK-STAT pathway in renal cells is unknown. To address this, human ADPKD-derived epithelial cells were treated with curcumin at 50μΜ for 6 hours, this concentration was used because it is the lowest dose that consistently caused a reduction in cystic growth (Figure 1 ). We found that curcumin acted as a potent inhibitor of activity causing an almost complete inhibition of tyrosine phosphorylation of
STAT3
following oncostatin M treatment (OSM at 10ng/ml -all OSM treatment subsequently will be at this fixed concentration) ( Figure 2A ); OSM was used to activate STAT3 tyrosine phosphorylation (18). These data therefore demonstrate that curcumin is a STAT3 inhibition in a variety of renal epithelial cells.
To gain a deeper understanding of the kinetics of the observed inhibition, we performed a dose-curve and found that as low as 25μΜ of curcumin was enough to cause at least 50% reduction in the phosphorylation of STAT3 when compared with DMSO vehicle-control ( Figure  2B and quantification). We treated cells with 10μΜ of curcumin, but this did not significantly affect STAT3 tyrosine phosphorylation (data not shown). Next to understand how quickly curcumin can inhibit STAT3 we performed a time-curve experiment. 1 hour of curcumin treatment (50μM) is sufficient to inhibit STAT3 phosphorylation ( Fig 2C) . Taken together, these experiments suggested that 50μM of curcumin is sufficient to inhibit JAK-STAT signalling, the fact that the inhibition happens within 1 hour suggests that curcumin may block JAK-STAT directly.
Curcumin
inhibits tyrosine phosphorylation of STAT3 via JAK2. The underlying mechanism to explain how curcumin inhibits STAT3 in ADPKD is unknown. Our biochemical studies showed that total STAT3 protein levels are unaffected following curcumin treatment (Fig 2) , therefore curcumin is likely to work upstream of STAT3 and specifically it might affect the kinases that phosphorylate it. To investigate this we studied JAK2, a tyrosine kinase upstream of STAT3 responsible for phosphorylating STAT3. Curcumin within 1 hour caused a drastic decrease in detergent-soluble JAK2, which was almost complete at 100μM and 50μM and only partial at 25μM of curcumin (Fig 3 and quantification) . The effect of curcumin on JAK2 ( Figure 3 ) mirrors those of STAT3 phosphorylation inhibition ( Fig 2B) . Given that JAK2 is required for STAT3 phosphorylation, we reasoned that the mechanism by which curcumin inhibits STAT3 activity, at least in part, is via inhibition of JAK2.
Curcumin does not interfere JAK2 levels but makes JAK2 insoluble.
Next, we wished to understand how curcumin affects JAK2. Since the levels of soluble JAK2 are reduced in cells treated with curcumin, we hypothesized that one possible mechanism of action may involve causing JAK2 to degrade. To investigate this, we treated renal tubular epithelial cells with MG132, which is a proteasome inhibitor and thus addition of MG132 is likely to stabilise proteins destined to be degraded via the proteosome. We expected MG132 will cause JAK2 to become stabilised if JAK2 was targeted to the proteasome following curcumin treatment. However, MG132 in the presence of curcumin did not rescue JAK2, suggesting that JAK2 is not being proteasomally processed in curcumin treated cells ( Fig. 4A ). Moreover, STAT3 phosphorylation was not changed following inhibition of the proteasome, further suggesting that proteosomal targeting is not part of the mechanism of action of curcumin ( Fig  4A) . To ensure that MG132, was indeed inhibiting the proteasome we blotted for ubiquitin, the level of protein ubiquitination should increase visibly when the proteasome is inhibited sufficiently. Indeed, we found that total levels of ubiquitinated proteins were increased in MG132 treated cells ( Fig   4A) , thus validating the results. It is of interest to mention that treatment of cells with curcumin also caused an accumulation of ubiquitinated proteins, suggesting that curcumin interferes with the processing of, at least some, proteins ( Fig 4A) . We also inhibited the lysosome (using Baffilomycin A), given that JAK2 has been shown to be lysosomally processed in other settings, however we did not detect any appreciable effects (data not shown). Collectively these data demonstrate that curcumin inhibits JAK2/STAT3 in a proteasomeindependent manner.
Curcumin has previously been shown to cause precipitation of proteins into aggresomes (19, 20) . To test whether JAK2 was moved into an insoluble aggregated state, we next performed immunocytochemistry in cells treated either with DMSO control or 1, 3 or 6 hours treatment with 50μM of curcumin. JAK2 was localised at the plasma membrane (arrow, Fig 4B, top left panel) in vehicle-treated cells. However, 1 hour of curcumin treatment was sufficient to cause JAK2 to move into puncta and aggregatate, these aggregates known as aggresomes became fewer but larger at 3 and 6 hours post curcumin treatment ( Fig  4B) . Our data therefore suggest that curcumin causes JAK2 to become inactivated by moving into an insoluble aggregated state.
JAK2 is highly expressed by renal tubular cystic epithelial cells in vivo.
Next, we wondered if JAK2 may be involved in the development of cysts in vivo. To determine whether renal cystic epithelial cells express JAK2, we stained kidney sections from the Pkd1 nl/nl mouse model (21) and associated healthy littermate control kidneys with anti-JAK2 antibodies.
Kidneys from 5 weeks old mice, with intermediate disease, and 10 weeks old with advance disease were studied, as previously described. (4) We found that JAK2 is widely expressed by renal epithelial cells and it is strongly localising in renal cystic tubular epithelial cells (Fig. 5 ). These data therefore show that JAK2 is highly expressed by cystic epithelial cells and therefore its inhibition is likely to be of therapeutic benefit in ADPKD.
Discussion
Over the years, phytochemicals have been used to inhibit, prevent or reverse disease processes. Curcumin is a phytochemical that targets a number of molecules exhibiting antiinflammatory activity. Additionally, it was found to have strong anti-cystic effects in murine models of ADPKD (11) and is currently being trialled (phase 4) in children and young patients with ADPKD-associated vascular complications. Because of curcumin's anti-inflammatory activity, it has been proposed as a treatment for ADPKD. One advantage of using curcumin is the possibility of using it long term due to the fact that no appreciable side effects are known. Indeed curcumin has been safely used in cooking without reported problems (22).
However, the reduced bioavailability of curcumin (23,24), makes it less attractive as a therapeutic agent when compared with small molecule inhibitors. Therefore, understanding how curcumin exerts renal protection in patients with ADPKD will allow us to uncover additional therapeutic targets some with increased bioavailability.
JAK-STAT
is an evolutionarily conserved pathway which is misregulated in a number of conditions such as cancer, arthritis and other inflammatory diseases (25). The STAT transcription factors become activated by tyrosine phosphorylation which is mediated by one of the tyrosine kinases JAK1-JAK3 or Tyk2. Because of the involvement of JAK-STAT in multiple diseases, several JAK inhibitors have been developed over the years, including the approved Ruxolitinib, Tofacitinib and Baracitinib (26-29). Moreover additional JAK inhibitors are in clinical trials, thus making JAK-STAT a therapeutically tractable pathway. Therefore, repurposing of a JAK inhibitor may be possible in patients with ADPKD.
In this paper we find that curcumin targets JAK2 by causing it to become inactive leading to reduced STAT3 activity. Given that STAT3 may be cystogenic, (8, 25, 30, 31) , it stands to speculate that some of the protection offered by curcumin may be via inhibition of STAT3 activity. However, high doses of curcumin are needed to inhibit STAT3, as shown in our study (25-100μM) and gaining these concentrations in plasma is difficult, given curcumin's reduced bioavailability (24). Leonhard et al however used an even lower concentration of 10μM and observed kidney protection (11). This may be explained by the accumulative effect of curcumin due to multiple dosing or otherwise the protection offered by curcumin was JAK-STAT independent.
Mechanistically we have found that curcumin causes JAK2 to move into an insoluble fraction consistent with the generation of multi-molecular structures or aggresomes. Therefore, we propose a model whereby curcumin takes JAK2 temporarily out of action by causing it to aggregate, without causing JAK2 to degrade which is an irreversible consequence. Temporarily inhibiting JAK2 may explain why curcumin is not cytotoxic, allowing JAK2 to become reactivated when needed. Likewise, others have reported that curcumin-treated cancer cells respond by inhibiting STAT3, a curcumin-induced effect which is fully reversible (14). How curcumin causes abnormally activated JAK2 to aggregate is currently unknown. Based on previous literature we hypothesize that curcumin disturbs JAK2 intramolecular interactions. Curcumin has been shown to be neuroprotective, by preserving gross intramolecular conformation of beta amyloids, while disrupting the intermolecular arrangements, a phenomenon which is very similar to the effects of Zn 2+ ions, as reported previously (20). Likewise, curcumin can alter the structure of lipoproteins by interacting with the soluble intermediates, thus altering their aggregation patterns (19) . Similarly, A20, which is an antiinflammatory zinc-finger protein is shown to cause aggregation of NFκB (an inflammatory transcription factor) and mediate vascular protection (32). We therefore propose that a similar mechanism may be in place also in renal tubular epithelial cells to cause aggregation of JAK2.
In conclusion curcumin is shown to be a potent inhibitor of cystic growth in vitro by inhibiting JAK2, which is highly expressed in the ADPKD murine kidneys. Therefore, our work suggests that specific JAK2 inhibitors need to be investigated in ADPKD.
METHODS
Cell lines.
Conditionally-immortalized ADPKD-derived lines (OX161 and SKI-001) (33) are tubular epithelial cells isolated from human kidneys and immortalized by transduction at an early passage (P1-4) with a retroviral vector containing a temperaturesensitive large T antigen and the catalytic subunit of human telomerase (34). The F1-Pkd1 WT renal epithelial cells were previously isolated from kidney papillae of the Pkd1fl/fl mouse (B6.129S4-Pkd1tm2Ggg/J; the Jackson Laboratory) and were immortalized with the lentiviral vector VVPW/mTert expressing the mTert; to delete Pkd1 and produce F1/Pkd1-/cells they were subsequently transfected with VIRHD/HY/Silntβ1/2363 lentivectors followed by hydromycin selection (35).
Cyst assays. Cyst assays were performed as previously described (4). In brief, for ADPKD cystic cell lines, 2 human lines namely OX161, SKI-001, and one mouse line F1-Pkd1 -/were used. OX161 and SKI-001 were kept at 33 o C F1-Pkd1-/-were at 37 o C. Healthily growing cells were trypsinised and re-suspended in DMEM media containing 10% FBS (no antibiotics) and counted using a haemocytometer. Subsequently 2x10 4 cells per well were mixed with basement Matrigel (354230, BD biosciences). Prior to use the Matrigel was left to thaw on ice and once cells were added it was immediately loaded onto the 96 well plate, allowing it to polymerise. 100μl of DMEM media supplemented with 10% FBS was added to each well and cells returned to cell incubator for 24 hours to allow them to recover. After 24 hours, the media was aspirated and replaced with fresh media (DMEM + 10% FBS) supplemented with either vehicle (DMSO) or curcumin (Sigma). The cells were photographed before every media change and every two days, the media was replaced with fresh media containing either curcumin or DMSO.
Immunohistochemistry/immunofluo rescence. Cells grown on coverslips were fixed with ice-cold methanol prior to blocking in 2% milk/TBST for 30 minutes and incubated with primary antibodies overnight at 4 o C. Antibodies used was anti-rabbit JAK2 (3230S, cell Signalling, D2E12). Cells were washed and incubated with secondary which was an anti-rabbit AF594 (A-11037, Invitrogen
(1:250) antibody. Microscopy was carried out using a confocal microscope. Immunohistochemistry using a JAK2 antibody (3230S, Cell Signalling) was performed as previously described (4).
Western blotting and curcumin treatment. Cells were analysed by Western blotting with previously reported protocols (36-39). In brief, cells were lysed using ice-cold Lysis Buffer (50mM Tris (pH 7.4) 250mM NaCl, 0.3% Triton X-100, 1mM EDTA) supplemented with protease inhibitor cocktail (Roche), freeze-thawed and sonicated. Whole cell lysates were boiled in 2xLaemmeli sample buffer for 5 minutes. Samples were resolved by SDS-PAGE and transferred using the Mini-PROTEAN system (Bio-Rad). Primary antibodies were anti-β-actin (ab8226, Abcam), anti-phosphorylated STAT3
(p-STAT3) (9145, Cell Signalling), anti-STAT3 (12640, Cell Signalling). Curcumin (08511-10MG, Sigma) was resuspended in DMSO and used at stated doses, DMSO served as vehicle control.
Animals. Pkd1 nl/nl , harboring an intronic neomycin-selectable marker, or wild type littermate controls were used (4,40). Pkd1 nl/nl or control mice were sacrificed at 5 or 10 weeks of age and kidneys collected, formalinfixed and paraffin embedded. 5-micron section were used for histological examination. All mouse experiments were done under the authority of a U.K. Home Office license.
Statistical analysis. Data were analysed using Prism GraphPad and Non-parametric, two-tailed, Mann-Whitney T-tests or one-way ANOVA were performed. Results with a P value of 0.05 or lower were considered statistically significant.
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Figures and legends
Figure 1: Curcumin slows down cyst growth in vitro. ADPKD-derived human epithelial cells were grown in BD-Matrigel to allow the formation of cysts to grow over time. All cysts formed were photographed at day 0, 2, 6 and 9; using an Olympus inverted microscope. Curcumin at 100, 50, 25 and 10μM or DMSO vehicle-control was added and cyst growth measured in A human OX161 B human SKI-001 and C mouse derived Pkd1 -/cell lines. One-way Anova with Bonferroni corrections was carried out and values lower that 0.05 were considered statistically significant. Symbol meaning: * P≤0.05, ** P≤0.01, *** P≤ 0.001, **** P≤0.0001.
Figure 2:
Curcumin is a potent STAT3 inhibitor. A. Oncostatin M (OSM, 10ng/ml) was used to stimulate phosphorylation of STAT3. Western blotting was performed (in human ADPKD-derived epithelial cells OX161, SKI-001 and mouse F1 Pkd1 -/-) anti-STAT3 phospho-tyrosine 705 antibody (pY STAT3), total STAT3 (STAT3) and
β actin which served as an internal loading control were used. B. SKI001 cells treated with either 100, 50 or 25μM of curcumin were subjected to blotting for STAT3, pYSTAT3 and β -actin control. Densitometric quantification of three independent blots was carried out. One-way Anova with Bonferroni corrections was performed, and values lower that 0.05 were considered statistically significant. C. SKI001 cells were treated with 100μM of curcumin for 1 or 3 or 6 hours and stimulated either with water vehicle control or 10ng/ml of OSM. pYSTAT3, STAT3 and β -actin were investigated by blotting. Quantification of three independent blots was carried out. One-way Anova with Bonferroni corrections was performed, and values lower that 0.05 were considered statistically significant. Symbol meaning: * P≤0.05, ** P≤0.01, *** P≤ 0.001, **** P≤0.0001.
Figure 3: Curcumin inhibits JAK2.
Western blotting of SKI001 lysates exposed to 100 or 50 or 25μM of curcumin was carried out, anti-JAK2 and β -actin were blotted. Quantification of three independent blots was carried out. One-way Anova with Bonferroni corrections was carried out and values lower that 0.05 were considered statistically significant. Symbol meaning: * P≤0.05, ** P≤0.01, *** P≤ 0.001, **** P≤0.0001.
Figure 4:
Curcumin controls JAK2 localisation. A. SKI001 cells were treated with OSM (10ng/ml), or MG132 (50μM) or curcumin (50μM) for 3 hours and lysates were subjected to immunoblotting. Antibodies against JAK2 pYSTAT3, STAT3, ubiquitin (indicator of proteasome inhibition control) and β -actin (internal loading control) were studied. B. SKI001 cells were either treated with DMSO vehicle control for 3 hours (3h) or curcumin for 1h or 3h or 6h, they were then snap frozen on ice-cold methanol, stained with anti-JAK2 rabbit antibody, followed by an anti-rabbit AF594 and imaged in an inverted fluorescent microscope. Red is anti-JAK2 (also in greyscale in lower panel), blue is nuclear counterstain (DAPI). Scale bars are 25μm. 
